Behavioral pharmacology of zolpidem relative to benzodiazepines: A Review

Pharmacology Biochemistry and Behavior

Volumn 61, Issue 3, 1998, Pages 253-269

  Rush, Craig R ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse potential; Benzodiazepines; Dependence; Drug discrimination; Humans; Hypnotics; Imidazopyridines; Liability; Memory impairment; Performance impairment; Self administration; Subjective effects; Zolpidem

Indexed keywords

ALPRAZOLAM; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRETAZENIL; CAFFEINE; CHLORDIAZEPOXIDE; CLONAZEPAM; COCAINE; DIAZEPAM; ESTAZOLAM; FLUNITRAZEPAM; LORAZEPAM; MIDAZOLAM; OXAZEPAM; PENTOBARBITAL; PLACEBO; QUAZEPAM; SARMAZENIL; TEMAZEPAM; TRIAZOLAM; ZOLPIDEM; ZOLPIDEM TARTRATE;

BABOON; BEHAVIOR; DRUG ABUSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG TOLERANCE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERFORMANCE; PRIORITY JOURNAL; RAT; REINFORCEMENT; REVIEW; SLEEP;

EID: 0344541101     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00102-6     Document Type: Article

References (154)

1. Arbilla, S.; Depoortere, H.; George, P.; Langer, S.: Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. Naunyn Schmiedebergs Arch. Pharmacol. 330:248-251; 1985.
2. Balkin T.; O'Donnell V.; Wesensten N.; McCann, U.; Belenky G.: Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology (Berlin) 107: 83-88; 1992.
3. Barnas, C.; Rossmann, M.; Roessler, H.; Riemer, Y.; Fleischhacker, W. W.: Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: Familiarity and preference. J. Clin. Psychopharmacol. 12:397-402; 1992.
4. Bechelli, L. P.; Navas, F.; Pierangelo, S. A.: Comparison of the reinforcing properties of zopiclone and triazolam in alcoholics. Pharmacology 27(Suppl. 2):235-241; 1983.
5. 3H] Ro 15-1788) in the mouse brain: Preferential affinity of zolpidem for the omega 1 (BZD1) subtype. J. Pharmacol. Exp. Ther. 245: 1033-1041; 1988.
6. 1) subtype. J. Pharmacol. Exp. Ther. 245:1033-1041; 1988.
7. Benavides, J.; Abadie, P.; Baron, J. C.; Scatton, B.: In vivo interaction of zolpidem with φ (benzodiazepine) site subtypes. In: Freeman, H.; Puech, A. J.; Roth, T., eds. Zolpidem: An update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier; 1996:33-44.
8. Berlin, I.; Warot, D.; Hergueta, T.; Molinier, P.; Bagot, C.; Puech, A. J.: Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J. Clin. Psychopharmacol. 13:100-106; 1993.
9. A receptor subtypes and the mechanism of action of zolpidem. In: Freeman, H.; Puech, A. J.; Roth, T., eds. Zolpidem: An update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier; 1996:21-32.
10. Bigelow, G.; Stitzer, M.; Lawrence, C.; Krasnegor, N.; D'Lugoff, B.; Hawthorne, J.: Narcotics addiction treatment: Behavioral methods concurrent with methadone maintenance. Int. J. Addict. 15:427-437; 1980.
11. Biggio, G.; Concas, A.; Corda, M. G.; Serra, M.: Enhancement of GABAergic transmission by zolpidem, an imidazopyridine with preferential affinity for type I benzodiazepine receptors. Eur. J. Pharmacol. 161:173-180; 1989.
12. Brady, J. V.; Hienz, R. D.; Ator, N. A.: Stimulus functions of drugs and the assessment of abuse liability. Drug Dev. Res. 20:231-249; 1990.
13. Brady, J. V.; Lukas, S. E.; Hienz, R. D.: Relationship between reinforcing properties and sensory/motor toxicity of CNS depressants: Implications for the assessment of abuse liability. In: Harris, L. S., ed. Problems of drug dependence. National Institute on Drug Abuse Monograph No. 43, DHHS Publiation No. (ADM)83-1284; pp. 196-202. Washington, DC: U.S. Government Printing Office; 1983.
14. Busto, U.; Seller, E. M.: Pharmacokinetic determinants of drug abuse and dependence. Clin. Pharmacokinet. 11:144-153; 1986.
15. Cardinale, V.: Drug topics redbook. Montvale, NJ: Medical Economics; 1996:98.
16. Chan, A. W.: Effects of combined alcohol and benzodiazepine: A review. Drug Alcohol Depend. 13:315-341; 1984.
17. Cohen, C.; Sanger, D. J.: Tolerance, cross-tolerance and dependence measure by operant responding in rats treated with triazolam via osmotic pumps. Psychopharmacology (Berlin) 115:86-94; 1994.
18. Cox, A.; Boyland, P.; Gent, J. P.; Feely, M.: An investigation of anti-convulsant tolerance to zolpidem I mice. Br. J. Pharmacol. 95:667P; 1988.
19. Dar, M. S.: Selective antagonism of acute ethanol-induced motor disturbances by centrally administered Ro 15-4513 in mice. Pharmacol. Biochem. Behav. 42:473-479; 1992.
20. Darke, S. G.; Ross, J. E.; Hall, W. D.: Benzodiazepine use among injecting heroin users. Med. J. Aust. 162:645-647; 1995.
21. 3H]zolpidem. J. Pharmacol. Exp. Ther. 247:309-322; 1988.
22. de Wit, H.; Bodker, B.; Ambre, J.: Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology (Berlin) 107:352-358; 1992.
23. de Wit, H.; Dudish, S.; Ambre, J.: Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology (Berlin) 112:324-330; 1993.
24. de Wit, H.; Griffiths, R. R.: Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend. 28:83-111; 1991.
25. Dunbar, G. C.; Perera, M. H.; Jenner, F. A.: Patterns of benzodiazepine use in Great Britain as measured by a general population survey. Br. J. Psychiatry 155:836-841; 1989.
26. DuPont, R.: Abuse of benzodiazepines: The problems and the solutions. Am. J. Drug Alcohol Abuse 14(Suppl. 1):1-69; 1988.
27. Edwards, J. G.: Adverse effects of antianxiety drugs. Drugs 22:495-514; 1981.
28. Evans, S. M.; Funderburk, F. R.; Griffiths, R. R.: Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability. J. Pharmacol. Exp. Ther. 255:1246-1255; 1990.
29. Evans, S. M.; Critchfield, T. S.; Griffiths, R. R.: Abuse liability assessment of anxiolytics/hypnotics: Rationale and laboratory lore. Br. J. Addict. 86:1625-1632; 1991.
30. Fairweather, D. B.; Kerr, J. S.; Hindmarch, I.: The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur. J. Clin. Pharmacol. 43:597-601; 1992.
31. Farré, M.; Cami, J.: Pharmacokinetic considerations in abuse liablity evaluations. Br. J. Addict. 86:1601-1606; 1991.
32. Fischman, M. W.; Mello, N. K.: Testing for abuse liability of drugs in humans. National Institute on Drug Abuse Monograph No. 92, Department of Health and Human Services Publication No. (ADM)89-1613. Washington, DC: U.S. Government Printing Office; 1989.
33. Fleming, J. A.: Triazolam abuse. Can. Med. Assoc. J. 129:324-325; 1983.
34. Fraisse, J.; Garrigou-Gadenne, D.; Thénot, J. P.: Pharmacokinetic and metabolic profile of zolpidem. In: Freeman, H.; Puech, A. J.; Roth, T., eds. Zolpidem: An update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier; 1996:45-58.
35. Frey, J. M.; Mintzer, M. Z.; Griffiths, R. R.: Zolpidem is differentiated from triazolam using a human drug discrimination procedure. Paper presented at the annual meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico; 1996.
36. Ghoneim, M. M.; Mewaldt, S. P.: Benzodiazepines and human memory: A review. Anesthesiology 72:926-938; 1990.
37. Glennon, R. A.; Jarbe, T. U. C.; Frankenheim, J.: Drug discrimination: Applications to drug abuse research. Research Monograph 116. National Institute on Drug Abuse. Public Health Service: Alcohol, Drug Abuse, and Mental Health Administration (DHHS (ADM) 92-1878). Rockville, MD: U.S. Department of Health and Human Services; 1991.
38. Graham, A. V.; Parran, T. V.; Jaen, C. R.: Physician failure to record alcohol use history when prescribing benzodiazepines. J. Subst. Abuse 4:179-185; 1992.
39. Grant, B. F.; Harford, T. C.: Concurrent and simultaneous use of alcohol with sedatives and with transquilizers: Results of a national survey. J. Subst. Abuse 2:1-14; 1990.
40. Greenblatt, D. J.; Harmatz, J. S.; Engelhardt, N.; Shader, R. I.: Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Arch. Gen. Psychiatry 46:326-332; 1989.
41. Greenblatt, D. J.; Harmatz, J. S.; Shader, R. I.: Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: Therapeutic considerations (Part I). Clin. Pharmacokinet. 21:165-177; 1991.
42. Greenblatt, D. J.; Harmatz, J. S.; Shader, R. I.: Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: Therapeutic considerations (Part II). Clin. Pharmacokinet. 21:262-273; 1991.
43. Greenblatt, D. J.; Harmatz, J. S.; Shapiro, L.; Englehardt, N.; Gouthro, T. A.; Shader, R. I.: Sensitivity to triazolam in the elderly. N. Engl. J. Med. 324:1691-1698; 1991.
44. Greenblatt, D. J.; Harmatz, J. S.; Wright, C. E.; Harrel, L.; Shader, R. I.: Does zolpidem have unique clinical properties? -A pharmacodynamic comparison with triazolam and placebo. Clin. Pharmacol. Ther. 59:178; 1996.
45. Griffiths, R. R.: Benzodiazepines: Long-term use among patients is a concern and abuse among polydrug abusers is not trivial. Psychopharmacology (Berlin) 118:116-117; 1995.
46. Griffiths, R. R.; Lamb, R. J.; Ator, N. A.; Roache, J. D.; Brady, J. V.: Relative abuse liability of triazolam: Experimental assessment in animals and humans. Neurosci. Biobehav. Rev. 9:133-151; 1985.
47. Griffiths, R. R.; Lamb, R. J.; Sannerud, C. A.; Ator, N. A.; Brady, J. V.: Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology (Berlin) 103:154-161; 1991.
48. Griffiths, R. R.; Lukas, S. E.; Bradford, L. D.; Brady, J. V.; Snell, J. D.: Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology (Berlin) 75:101-109; 1981.
49. Griffiths, R. R.; Sannerud, C. A.; Ator, N. A.; Brady, J. V.: Zolpidem behavioral pharmacology in baboons: Self-injection, discrimination, tolerance and withdrawal. J. Pharmacol. Exp. Ther. 260:1199-1208; 1992.
50. Griffiths, R. R.; Weerts, E. M.: Benzodiazepine self-administration in humans and laboratory animals - Implications of problems of long-term use and abuse. Psychopharmacology (Berlin) 134:1-37; 1997.
51. Griffiths, R. R.; Wolf, B.: Relative abuse liability of different benzodiazepines in drug abusers. J. Clin. Psychopharmacol. 10:237-243; 1990.
52. Haefely, W. E.: Pharmacology of the benzodiazepine receptor. Eur. Arch. Psychiatr. Neurol. Sci. 238:294-301; 1989.
53. Hollister, L. E.; Muller-Oerlinghausen, B.; Rickels, K.; Shader, R. I.: Clinical uses of benzodiazepines. J. Clin. Psychopharmacol. 13:1S-169S; 1993.
54. Holtzman, S. G.; Locke, K. W.: Neural mechanisms of drug stimuli: Experimental approaches. In: Colpaert, F. C.; Balster, R. L., eds. Transduction mechanisms of drug stimuli. Berlin: Springer Verlag; 1988:138-153.
55. Iguchi, M.; Handelsman, L.; Bickel, W.; Griffiths, R.: Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 32:257-266; 1993.
56. A receptors in acutely dissociated rat striatal and cerebellar neuron. Neuropharmacology 35:137-145; 1996.
57. Jaffe, J. H.: Drug addiction and drug abuse. In: Goodman Gilman, A.; Rail, T. W.; Nies, A. A.; Taylor, P., eds. The pharmacological basis of therapeutics, 8th ed. New York: Macmillan Publishing Company; 1990:522-573.
58. Jankowska, E.; Iwinska, K.; Stefanski, R.; Biekowski, P.; Kostowski, W.: The effect of zolpidem on motor activity, ethanol drinking and ethanol discriminative stimulus in rats. Behav. Pharmacol. 7:54; 1996.
59. Jasinski, D. R.; Henningfield, J. E.: Human abuse liability assessment by measurement of subjective and physiological effects. In: Fischman, M. W.; Mello, N. K., eds. Testing for abuse liability of drugs in humans. National Institute on Drug Abuse Monograph No. 92, Department of Health and Human Services Publication No. (ADM)89-1613. Washington, DC: U.S. Government Printing Office; 1989:73-100.
60. Johanson, C. E.: Discriminative stimulus effects of diazepam in humans. J. Pharmacol. Exp. Ther. 257:634-643; 1991.
61. Johanson, C. E.: Further studies on the discriminative stimulus effects of diazepam in humans. Behav. Pharmacol. 2:357-367; 1991.
62. Kales, A.; Scharf, M. B.; Kales, J. D.; Soldatos, C. R.: Rebound insomnia: A potential hazard following withdrawal of certain benzodiazepines. JAMA 241:1692-1695; 1979.
63. Kamien, J. B.; Bickel, W. K.; Hughes, J. R.; Higgins, S. T.; Smith, B. T.: Drug discrimination by humans compared to non-humans: Current status and future directions. Psychopharmacology (Berlin) 111:259-270; 1993.
64. Kamien, J. B.; Bickel, W. K.; Smith, B. J.; Badger, G. J.; Hughes, J. R.: Secobarbital in humans discriminating triazolam under two-response and novel-response procedures. Pharmacol. Biochem. Behav. 58:983-991; 1997.
65. Katz, J.: Models of relative reinforcing efficacy of drugs and their predictive utility. Behav. Pharmacol. 1:283-301; 1990.
66. Koob, G. F.; Percy, L.; Britton, K. T.: The effects of Ro 15-4513 on the behavioral actions of ethanol in an operant reaction time task and a conflict test. Pharmacol. Biochem. Behav. 31:757-760; 1989.
67. Kummer, J.; Guendel, L.; Linden, J.; Eich, F. X.; Attali, P.; Coquelin, J. P.; Kyrein, H. J.: Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J. Int. Med. Res. 21:171-184; 1993.
68. Lader, M. H.; Hindmarch, I.: Memory, psychomotor and cognitive functions after treatment with zolpidem. In: Freeman, H.; Puech, A. J.; Roth, T., eds. Zolpidem: An update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier; 1996:59-72.
69. Lamb, R. J.; Preston, K. L.; Schindler, C. W.; Meisch, R. A.; Davis, F.; Katz, J. L.; Henningfield, J. E.; Goldberg, S. R.: The reinforcing and subjective effects of morphine in postaddicts: A dose-response study. J. Pharmacol. Exp. Ther. 259:1165-1173; 1991.
70. Langtry, H. D.; Benfield, P.: Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291-313; 1990.
71. Launchbury, A. P.; Morton, F. S. S.; Lacy, J. E.: The development of temazepam gelthix. Manufacturing Chemist, December; 1989:38-40.
72. Linnoila, M. I.: Benzodiazepines and alcohol. J. Psychiatr. Res. 24:121-127; 1990.
73. Lister, R. G.: The amnestic action of benzodiazepines in man. Neurosci. Biobehav. Rev. 9:87-94; 1985.
74. A receptor supramolecular complex: A consideration of the new omega 1-receptor selective imidazopyridine hypnotic zolpidem. Pharmacol. Biochem. Behav. 29:781-783; 1988.
75. Lobo, B. L; Green, W. L.: Zolpidem: Distinct from triazolam? Ann. Pharmacother. 31:625-631; 1997.
76. Maarek, L.; Cramer, P.; Attali, P.; Coquelin, J. P.; Morselli, P. L.: The safety and efficacy of zolpidem in insomniac patients: A long-term open study in general practice. J. Int. Med. Res. 20: 162-170; 1992.
77. Mancinelli, A.; Guiso, G.; Garattini, S.; Urso, R.; Caccia, S.: Kinetic and pharmacological studies on estazolam in mice and man. Xenobiotica 15:257-265; 1985.
78. A receptor sutypes immunopurified from rat brain with α-subunit antibodies have unique pharmacological properties. Neuron 7:667-676; 1991.
79. Merlotti, L.; Roehrs, T.; Koshorek, G.; Zorick, F.; Lamphere, J.; Roth, T.: The dose effects of zolpidem on the sleep of healthy normals. J. Clin. Psychiatry 9:9-14; 1989.
80. Miller, N. S.; Giannini, A. J.: Drug misuse in alcoholics. Int. J. Addict. 26:851-857; 1991.
81. Mintzer, M. Z.; Frey, J. M.; Yingling, J. E.; Griffiths, R. R.: Triazolam and zolpidem: A comparison of their psychomotor, cognitive and subjective effects in healthy volunteers. Behav. Pharmacol. 8:561-574; 1997.
82. Monti, J. M.; Attali, P.; Monti, D.; Zipfel, A.; Giclais, B.; Morselli, P. L.: Zolpidem and rebound insomnia: A double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 27:166-175; 1994.
83. Morgan, K.: Hypnotics in the elderly: What cause for concern. Drugs 40:688-696; 1990.
84. Morgan, K.; Dallosso, H.; Ebrahim, S.; Arie, T.; Fentem, P. H.: Prevalence, frequency, and duration of hypnotic drug use among the elderly living at home. Br. Med. J. 296:601-602; 1988.
85. Mumford, G. K.; Silverman, K.; Griffiths, R. R.: Reinforcing, subjective, and performance effects of lorazepam and diphenhydramine in humans. Exp. Clin. Psychopharmacol. 4:421-430; 1996.
86. Mumford, G. K.; Evans, S. M.; Fleishaker, J. C.; Griffiths, R. R.: Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther. 57:356-365; 1995.
87. Navaratnam, V.; Foong, K.: Adjunctive drug use among opiate addicts. Curr. Med. Res. Opin. 11:611-619; 1990.
88. Navaratnam, V.; Foong, K.: Opiate dependence - The role of benzodiazepines. Curr. Med. Res. Opin. 11:620-630; 1990.
89. Nikaido, A. M.; Ellinwood, E. H., Jr.; Heatherly, D. G.; Gupta, S. K.: Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology (Berlin) 100:90-97; 1990.
90. Oliveto, A. H.; Bickel, W. K.; Hughes, J. R.; Higgins, S. T.; Fenwick, J. W.: Triazolam as a discriminative stimulus in humans. Drug Alcohol Depend. 30:133-142; 1992.
91. Oliveto, A. H.; Bickel, W. K.; Kamien, J. B.; Hughes, J. R.; Higgins, S. T.: Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure. Psychopharmacology (Berlin) 114:417-423; 1994.
92. Perrault, G.; Morel, E.; Sanger, D. J.; Zivkovic, B.: Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J. Pharmacol. Exp. Ther. 263:298-303; 1992.
93. Physician's desk reference.: Oradell, NJ: Medical Economics Company, Inc.; 1997.
94. Poirrier, R.; Franck, G.; Scheldewaert, R.; Jolie, A.; Tomas, M.: The effect of long-term zolpidem treatment on nocturnal polysomnography and daytime vigilance in patients with psychophysiological insomnia. Acta Ther. 20:77-86; 1994.
95. Praplan-Pahud, J.; Forster, A.; Gamulin, Z.; Tassonyi, E.; Sauvanet, J. P.: Preoperative sedations before regional anaesthesia: Comparison between zolpidem, midazolam and placebo. Br. J. Anaesth. 64:670-674; 1990.
96. Preston, K.; Bigelow, G.: Subjective and discriminative effects of drugs. Behav. Pharmacol. 2:293-313; 1991.
97. Pringuey, D.; Sallliere, D.: Tolerability and safety of zolpidem. In: Freeman, H.; Puech, A. J.; Roth, T., eds. Zolpidem: An update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier; 1996:195-214.
98. Rifkin, A.; Doddi, S.; Karajgi, B.; Hasan, N.; Alvarez, L.: Benzodiazepine use and abuse by patients at outpatient clinics. Am. J. Psychiatry 146:1331-1332; 1989.
99. Roache, J.; Griffiths, R. R.: Abuse liability of anxiolytics and sedative/hypnotics: Methods assessing the likelihood of abuse. In: Fischman, M. W.; Mello, N. K., eds. Testing for abuse liability of drugs in humans. National Institute on Drug Abuse Monograph No. 92, Department of Health and Human Services Publication No. (ADM)89-1613. Washington, DC: U.S. Government Printing Office; 1989:123-146.
100. Roache, J. D.; Meisch, R. A.: Findings from self-administration research on the addiction potential of benzodiazepines. Psychiatr. Ann. 23:153-157; 1995.
101. Roache, J. D.; Meisch, R. A.; Henningfield, J. E.; Jaffe, J. H.; Klein, S.; Sampson, A.: Reinforcing effects of triazolam in sedative abusers: Correlation of drug liking and self-administration measures. Pharmacol. Biochem. Behav. 50:171-179; 1995.
102. Roehrs, T.; Merlotti, L.; Zorick, F.; Roth, T.: Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berlin) 116:130-134; 1994.
103. Roehrs, T.; Vogel, G.; Sterling, W.; Roth, T.: Dose effects of temazepam in transient insomnia. Arzneimittelforschung 40:859-862; 1990.
104. Roger, M.; Attali, P.; Coquelin, J. P.: Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin. Ther. 15:127-136; 1993.
105. Rosenberg, R. C.: Differential expression of benzodiazepine anticonvulsant cross-tolerance according to time following flurazepam or diazepam treatment. Pharmacol. Biochem. Behav. 51:363-368; 1995.
106. Roth, T.; Roehrs, T.; Vogel, G.: Zolpidem in the treatment of transient insomnia: A double-blind, randomized comparison with placebo. Sleep 18:246-251; 1995.
107. Rowlett, J. K.; Woolverton, W. L.: Discriminative-stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam in monkeys and rats. J. Pharmacol. Exp. Ther. 280:162-173; 1997.
108. Rush, C. R.; Baker, R. W.; Ali, J. A.; Wright, K.: Trazodone, zolpidem, and triazolam in humans: Acute behavioral effects and abuse potential. Unpublished data; 1998.
109. Rush, C. R.; Critchfield, T. S.; Troisi, J. R., II; Griffiths, R. R.: Discriminative stimulus effects of diazepam and buspirone in normal volunteers. J. Exp. Anal. Behav. 63:277-294; 1995.
110. Rush, C. R.; Griffiths, R. R.: Zolpidem, triazolam, and temazepam: Behavioral and subject-rated effects in normal volunteers. J. Clin. Psychopharmacol. 16:146-152; 1996.
111. Rush, C. R.; Griffiths, R. R.: Acute subject-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Exp. Clin. Psychopharmacol. 5:28-38; 1997.
112. Rush, C. R.; Madakasira, S.; Goldman, N. H.: Acute behavioral effects of estazolam and triazolam in non-drug abusing volunteers. Exp. Clin. Psychopharmacol. 4:300-307; 1996.
113. Rush, C. R.; Madakasira, S.; Goldman, N. H.; Woolverton, W. L.; Rowlett, J. K.: Discriminative-stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans. J. Pharmacol. Exp. Ther. 280:174-188; 1997.
114. Rush, C. R.; Madakasira, S.; Hayes, C. A.; Johnson, C. A.; Goldman, N. H.; Pazzaglia, P. J.: Trazodone and triazolam: Acute subject-rated and performance-impairing effects in healthy volunteers. Psychopharmacology (Berlin) 131:9-18; 1997.
115. Rush, C. R.; Mumford, G. K.; Griffiths, R. R.: Discriminative stimulus effects of triazolam, zolpidem, oxazepam and caffeine in humans. In: Harris, L., ed. Problems of drug dependence, 1995, National Institute on Drug Abuse Research Monograph Series, vol. 162. Rockville, MD: U.S. Government Printing Office; 1996:248; 1996.
116. Rush, C. R.; Rowlett, J. K.; Baker, R. W.: Discriminative-stimulus and subject-rated effects of zolpidem, triazolam, pentobarbital and caffeine in zolpidem-trained humans. Unpublished data; 1998.
117. Rush, C. R.; Ali, J. A.: Differential behavioral effects of quazepam and triazolam in humans. Experimental and Clinical Psychopharmacology (under review).
118. Salvö, P.; Costa, J.: Clinical pharmacokinetics and pharmacodynamics of zolpidem. Drug Disposit. 29:142-153; 1995.
119. Sanger, D. J.: Further investigation of the stimulus properties of chlordiazepoxide and zolpidem. Agonism and antagonism by two novel benzodiazepines. Psychopharmacology (Berlin) 93:365-368; 1987.
120. Sanger, D. J.; Zivkovic, B.: The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic. Psychopharmacology (Berlin) 89:317-322; 1986.
121. Sanger, D. J.; Zivkovic, B.: Discriminative stimulus properties of chlordiazepoxide and zolpidem. Agonist and antagonist effects of CGS 9896 and ZK 91296. Neuropharmacology 26:499-505; 1987.
122. Sanger, D. J.; Zivkovic, B.: Investigation of the development of tolerance to the actions of zolpidem and midazolam. Neuropharmacology 26:1513-1518; 1987.
123. A receptors. Neuropharmacology 31:693-700; 1992.
124. Sanger, D. J.; Joly, D.; Zivkovic, B.: Effects of zolpidem, a new imidazopyridine hypnotic, on the acquisition of a conditioned fear response in mice: Comparison with triazolam and CL 218,872. Psychopharmacology (Berlin) 90:207-210; 1986.
125. Sanger, D. J.; Perrault, G.; Morel, E.; Joly, D.; Zivkovic, B.: The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridine structure. Physiol. Behav. 41:235-240; 1987.
126. Sannerud, C. A.; Ator, N. A.: Drug discrimination analysis of midazolam under a three-lever procedure: I. Dose-dependent differences in generalization and antagonism. J. Pharmacol. Exp. Ther. 272:100-111; 1995.
127. Sannerud, C. A.; Cook, J. M.; Griffiths, R. R.: Behavioral differentiation of benzodiazepine ligands after repeated administration in baboons. Eur. J. Pharmacol. 167:333-343; 1989.
128. Sauvanet, J. P.; Langer, S. Z.; Morselli, P. L.: Imidazopyridines in sleep disorders. New York: Raven Press; 1988.
129. Scharf, M. B.; Roth, T.; Vogel, G. W.; Walsh, J. K.: A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J. Clin. Psychiatry 55:192-199; 1994.
130. Schechter, M. D.; Lovano, D. M.: Ethanol-chlordiazepoxide interactions in the rat. Pharmacol. Biochem. Behav. 23:927-930; 1985.
131. Schlich, D.; Heritier, C. L.; Coquelin, J. P.; Attali, P.: Long-term treatment of insomnia with zolpidem: A multicentre general practitioner study of 107 patients. J. Int. Med. Res. 19:271-279; 1991.
132. Schoch, P.; Moreau, J. L.; Martin, J. R.; Haefely, W. E.: Aspects of benzodiazepine receptor structure and function with relevance of drug tolerance and dependence. Biochem. Soc. Symp. 59:121-134; 1993.
133. Schuster, C. R.; Fischman, M. W.; Johanson, C. E.: Internal stimulus control and subjective effects of drugs. In: Thompson, T.; Johanson, C. E., eds. Behavioral pharmacology of human drug dependence, National Institute on Drug Abuse Research Monograph Series, 37. Rockville, MD: U.S. Department of Health and Human Services, National Institues of Health, National Institute on Drug Abuse; 1981:116-129.
134. Schuster, C. R.; Johanson, C. E.: Relationship between the discriminative stimulus properties and subjective effects of drugs. In: Colpaert, F. C.; Balster, R. L., eds. Transduction mechanisms of drug stimuli. Berlin: Springer Verlag; 1988:161-175.
135. Sellers, E. M.; Ciraulo, D. A.; DuPont, R. L.; Griffiths, R. R.; Kosten, T. R.; Romach, M. K.; Woody, G. E.: Alprazolam and benzodiazepine dependence. J. Clin. Psychiatry 54:64-75; 1993.
136. Shaw, S. H.; Curson, H.; Coquelin, J. P.: A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. Int. J. Med. Res. 20:150-161; 1992.
137. Smith, B. J.; Bickel, W. K.: Effects of alprazolam, caffeine, and zolpidem in humans trained to discriminate triazolam from placebo: Comparison of a two- and a novel-response procedure. Experimental and Clinical Psychopharmacology (Berlin) (under review).
138. Stephens, D. N.; Sanger, D. J.: The abuse and dependence liabilities of zolpidem. In: Freeman, H.; Puech, A. J.; Roth, T., eds. Zolpidem: An update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier; 1996:73-86.
139. Stephens, D. N.; Voet, B.: Differential effect of anxiolytic and non-anxiolytic benzodiazepine receptor ligands on performance on a differential reinforcement of low rate (DRL) schedule. Behav. Pharmacol. 5:4-14; 1994.
140. Stitzer, M. L.; Griffiths, R. R.; McLellan, A. T.; Grabowski, J.; Hawthorne, J. W.: Diazepam use among methadone maintenance patients: Patterns and dosages. Drug Alcohol Depend. 8:189-199; 1981.
141. Strang, J.; Seivewright, N.; Farrell, M.: Intravenous and other novel abuses of benzodiazepines: The opening of Pandora's box? Br. J. Addict. 87:1373-1375; 1992.
142. Suzdak, P. D.; Glowa, J. R.; Crawley, J. N.; Schwartz, R. D.; Skolnick, P.; Paul, S. M.: A selective imidazobenzodiazepine antagonist of ethanol in the rat. Science 234:1243-1247; 1986.
143. A receptor subtypes. J. Pharmacol. Exp. Ther. 275:761-767; 1995.
144. Troisi, J. R., II; Critchfield, T. S.; Griffiths, R. R.: Buspirone and lorazepam abuse liability in humans: Behavioral effects, subjective effects and choice. Behav. Pharmacol. 4:217-230; 1993.
145. Von Voigtlander, P. F.; Lewis, R. A.: A rapid screening method for the assessment of benzodiazepine receptor-related physical dependence in mice: Evaluation of benzodiazepine-related agonists and partial agonists. J. Pharmacol. Methods 26:1-5; 1991.
146. Walsh, J. K.; Muehlbach, M. J.; Schweizer, P. K.: Acute administrations of triazolam for daytime sleep of rotating shift workers. Sleep 7:223-229; 1984.
147. Ware, J. C.; Walsh, J. K.; Scharf, M. B.; Roehrs, T.; Roth, T.; Vogel, G. W.: Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin. Neuropharmacol. 20:116-125; 1997.
148. Weerts, E. M.; Grech, D. M.; Ator, N. A.: Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J. Pharmacol. Exp. Ther. 285:41-53.
149. Wesensten, N. J.; Balkin, T. J.; Belenky, G. L.: Effects of day-time administration of zolpidem versus triazolam on memory. Eur. J. Clin. Pharmacol. 48:115-122; 1995.
150. Wesensten, N. J.; Balkin, T. J.; Davis, H. Q.; Belenky, G. L.: Reversal of triazolam- and zolpidem-induced memory impairment by flumazenil. Psychopharmacology (Berlin) 121:242-249; 1995.
151. Wilkinson, C. J.: The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J. Clin. Psychiatry 56:309-318; 1995.
152. Woods, J. H.; Katz, J. L.; Winger, G.: Abuse liability of benzodiazepines. Annu. Rev. Pharmacol. Toxicol. 39:251-413; 1987.
153. Woods, J. H.; Katz, J. L.; Winger, G.: Benzodiazepines: Use, abuse, and consequences. Pharmacol. Rev. 44:151-347; 1992.
154. Woods, J. H.; Winger, G.: Abuse liability of flunitrazepam. J. Clin. Psychopharmacol. 17(Suppl. 2):1S-57S; 1997.